Mylan CEO Heather Bresch speaks to CNBC on Thursday about the controversy surrounding her company's 400-percent price hike to EpiPens over the past few years.
Colombia's government and leftist FARC rebels unveiled a peace deal to end a guerrilla war which almost made the country a failed state.
Some people are decrying Duterte's drugs crackdown and the casualties while others are in support of it, says Teneo Holdings' Roberto Herrera-Lim.
De La Salle University's Richard Heydarian says the Philippines' president is under pressure to deliver on promises to be tough on crime and shake-up bureaucracy.
Clovis Oncology shares shot up more than 26 percent Tuesday after the FDA accepted the company's new drug application.
CNBC's Meg Tirrell reports the details on Pfizer's deal for Medivation.
Philippine President Rodrigo Duterte railed against the United Nations after it called for an end to the wave of killings unleashed by his war on drugs.
Morgan Stanley upgraded Valeant Pharmaceuticals to overweight from equal weight.
The U.S. government will announce that it will allow more research into marijuana but will reject requests to loosen the drug's classification.
Elite athletes like those at the Olympics may be more prone to opioid addiction, says volleyball icon Gabby Reece. CNBC’s Dina Gusovsky reports.
The International Paralympic Committee announced the suspension of the entire Russian Paralympic team due to a rampant doping scandal.
Prescription drug prices are a mystery, but a new start up is disrupting prices for generic drugs across the country.
$21 billion is how much investors wiped off the firm after its trial to broaden the use of one of its most promising drugs failed.
Prescription drug prices are a mystery.But Blink Health, a free app and website, says it can save customers up to 90% on generic drugs. We ask brothers, and co-founders Geoffrey and Matthew Chaiken how they can get these low prices and if branded drugs could be next.
The opioid drug crisis could become a big hurdle for states wooing businesses by touting their great quality of life and workforce.
The IOC approved the entry of 271 Russian athletes, or 70 percent of the original team, for the Rio de Janeiro Olympics on Thursday after a doping scandal.
Infectious disease expert Dr. David Weber discusses Zika worries in Rio, outbreaks and precautions.
CNBC's Josh Lipton reports on "biohacking" in Silicon Valley where people are trying to improve their lives through new supplements.
The $75 billion Biogen may be vulnerable to a takeover, but it makes a risky target at a likely value approaching $90 billion.
Most claims of opioid dependence involved adults between the ages of 19 and 35.